Sage Therapeutics Jumps on Biogen's $469 Million Takeover Offer / Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up / Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies / Biogen dumps dubious Alzheimer's drug after profit-killing FDA scandal / Biogen to stop selling controversial Alzheimer's drug Aduhelm / Biogen Quits Controversial Alzheimer's Drug Aduhelm / Biogen to cease production of controversial Alzheimer's drug

Biogen

8 days ago

Bookmark

Share

Biogen is a company. It is part of the Health Care sector, specifically in the Biotechnology industry.

Key facts

employees: Try Pro to see estimate
revenues: Try Pro to see estimate
sector: Health Care
industry: Biotechnology
ESG score: Try Pro to see estimate
environmental score (ESG): Try Pro to see estimate
social score (ESG): Try Pro to see estimate
governance score (ESG): Try Pro to see estimate

See more facts

Extract data

Download datasets about Biogen:

Dataset of stocks from Biogen:

Biogen is one of the companies in Biotechnology, companies in Health Care and 3,456,835 companies in our database.

Talking Points

Home | Biogen
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

Related

Connected or similar to Biogen: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.